Surgery for retroperitoneal and pelvic lymph node metastases of colorectal cancer

AIM: to evaluate the effect of surgery for metastases in retroperitoneal and pelvic lymph nodes on overall and disease-free survival.PATIENTS AND METHODS: the analysis included 30 patients with retroperitoneal lymph node metastases of colorectal cancer. Synchronous metastases to the retroperitoneal lymph nodes, were diagnosed in 21/30 (70%).RESULTS: the median overall and disease-free survival in patients who underwent lymphodissection was 32 and 13 months, respectively. Recurrence occurred in 14/30 (47%) patients. One-, two-, three-year disease-free survival was 61 ± 11%, 20 ± 11%, 0%; general 95 ± 4%, 74 ± 14%, 37 ± 19%, relatively. The median disease-free survival in the group with isolated retroperitoneal lymph node lesion was 14 (9–29) months and 10 (6–18) months in the group with retroperitoneal lymph node metastases in combination with synchronous liver lesion. One-and three-year disease-free survival was the same in the groups and was 58 ± 15% and 0%, p = 0.2. The univariate analysis did not reveal any factors related to overall and disease-free survival.CONCLUSION: in a selected group of patients with colorectal cancer, with lesions of retroperitoneal lymph nodes, including resectable metastases to the other organs, surgery can be justified, since it is accompanied by a relatively low rate of complications. However, the small cohort requires further study..